mgl-3745

MGL-3745 is a **small molecule drug** developed as a selective thyroid hormone receptor beta (THR-β) agonist[1][4][12][16]. It is being investigated by Madrigal Pharmaceuticals, under license from Roche, primarily for the treatment of **nonalcoholic steatohepatitis (NASH)** and **hyperlipidemia type IIa**. These indications reflect efforts to target the underlying causes of fatty liver disease and metabolic dysfunction via liver-directed modulation of lipid metabolism, aiming to decrease hepatic steatosis and improve lipid profiles through selective THR-β activation[1][4][8][12][16]. MGL-3745 is considered a follow-on or next-generation compound following the clinical candidate resmetirom (MGL-3196), sharing the mechanism but remaining in preclinical development[1][8][16]. No clinical efficacy or safety data have been published, and no development has been reported beyond preclinical phases for its primary indications.

Brand names

MGL-3745MGL3745MGL 3745

Other names

MGL-3745MGL3745MGL 3745